Zacks Investment Research upgraded shares of Krystal Biotech (NASDAQ:KRYS) from a sell rating to a hold rating in a research note released on Wednesday, May 16th.
According to Zacks, “Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States. “
Separately, ValuEngine raised shares of Krystal Biotech from a sell rating to a hold rating in a report on Wednesday, May 2nd.
Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, May 7th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.27. equities analysts anticipate that Krystal Biotech will post -2.21 earnings per share for the current fiscal year.
In related news, insider Krish S. Krishnan bought 50,000 shares of the company’s stock in a transaction on Monday, March 19th. The stock was bought at an average cost of $11.00 per share, with a total value of $550,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director R Douglas Norby bought 9,000 shares of the company’s stock in a transaction on Wednesday, May 9th. The stock was bought at an average cost of $10.42 per share, with a total value of $93,780.00. The disclosure for this purchase can be found here. Company insiders own 45.80% of the company’s stock.
A hedge fund recently bought a new stake in Krystal Biotech stock. Millennium Management LLC acquired a new stake in shares of Krystal Biotech (NASDAQ:KRYS) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 25,268 shares of the company’s stock, valued at approximately $266,000. Millennium Management LLC owned 0.25% of Krystal Biotech as of its most recent filing with the Securities & Exchange Commission. 29.82% of the stock is currently owned by institutional investors and hedge funds.
About Krystal Biotech
Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in preclinical development to treat dystrophic epidermolysis bullosa, a genetic disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.